GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5264 MRS 2365Summary: Highly potent, selective P2Y1 receptor agonist -
B5265 MRS 2279Summary: Selective, high affinity competitive antagonist of the P2Y1 receptor -
B5266 MRS 2500 tetraammonium saltSummary: Highly potent and selective antagonist of the platelet P2Y1 receptor -
B5267 BVD 10Summary: NPY Y1 receptor antagonist,highly selective -
B5273 des-His1-[Glu9]-Glucagon (1-29) amideSummary: Glucagon receptor antagonist -
B5274 Rac1 Inhibitor W56Summary: inhibitor of Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1 -
B5280 GIP (1-39)Summary: Endogenous truncated form of the incretin hormone GIP -
B5281 GLP-2 (human)Summary: intestinal epithelium-specific growth factor -
B5282 GLP-2 (rat)Target: GLP-2 receptorSummary: intestinal epithelium-specific growth factor -
B5283 WRW4Summary: Selective antagonist of formyl peptide receptor 2 (FPR2) signaling

